Form 4: Amgen Director Mary E. Klotman Receives Stock Grant

Amgen Inc. director Mary E. Klotman acquired 665 shares of common stock through an immediate vesting of restricted stock units.

Summary

• Director Mary E. Klotman acquired 665 shares of Amgen Inc. common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs) granted under the company's 2009 Director Incentive Program.
• Following this transaction, the director's total beneficial ownership increased to 2,211 shares.
• The transaction was executed at a price of $0 per share as part of director compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company strategy or financial outlook.

Positives

• Increased equity alignment between the director and shareholders.
• Standardized compensation practice under the established 2009 Equity Incentive Plan.

Negatives

• None identified.

Risks

• General market risks associated with equity ownership in the biotechnology sector.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the large-cap biopharmaceutical industry to ensure board members maintain a vested interest in long-term corporate performance.

Comparison to Industry Standards

• The grant aligns with standard corporate governance practices for S&P 500 companies.
• The use of RSUs for director compensation is consistent with peers such as Gilead Sciences and Biogen.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• None

Key Dates

Keywords

Amgen, AMGN, Form 4, Director Compensation, Insider Transaction, Restricted Stock Units